Another interesting study is termed, “Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural Mesothelioma” by Srensen PG, Bach F, Bork E, Hansen HH – Cancer Treat Rep. 1985 Dec;69(12):1431-2. This is an excerpt: “Abstract – The consequence of doxorubicin and cyclophosphamide with the treatments for diffuse, malignant pleural mesothelioma was evaluated in any randomized study. All patients were treated in an outpatient basis and none had previously received antineoplastic treatment. All patients a measurable lesion other than pleural effusion. The procedure contained doxorubicin at a dose of 60 mg/m2 every 23 days, with a total dose of 550 mg/m2, or cyclophosphamide at the dose of 1500 mg/m2 every 25 days for 1 year. At disease progression treatments was changed into the alternate drug. The dose was increased or decreased in accordance with hematologic effects. Thirty of 32 patients were evaluable for response. Remissions just weren’t achieved in a patient. During treatment with doxorubicin, no patients developed cardiotoxicity, while one patient developed hemorrhagic cystitis during treatment with cyclophosphamide. Sepsis or bleeding weren’t witnessed in either within the treatment arms. Thus, the trial showed no antineoplastic activity of either doxorubicin or cyclophosphamide inside treating malignant pleural mesothelioma.”
Another interesting study is named, “Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to cure in vivo forms of human malignant mesothelioma and lung cancer.” By Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, Litzky LA, Kaiser LR, Albelda SM – Department of Medicine; University of Pennsylvania Infirmary, Philadelphia Am J Respir Cell Mol Biol. 1995 Jul;13(1):7-16. Is an excerpt: “Abstract – Previous research has shown adenoviral transfer of the herpes simplex virus thymidine kinase (HSVtk) gene combined with the anti-viral drug ganciclovir (GCV) is known to successfully treat established human mesothelioma tumors growing in the peritoneal cavities of severe combined immune deficient (SCID) mice. These bits of information raised a variety of questions crucial to the applicability, efficiency, and safety of the treatment strategy. In this report, we’ve further characterized using recombinant adenovirus carrying the HSVtk gene to take care of mesothelioma together with other localized malignancies. Our results indicate the fact that the Ad.RSVtk/GCV product is proficient at causing tumor regression in animals inoculated with another mesothelioma cell line in addition to a united states cell line which animals with bulky disease can be successfully treated. Effects are located with a lots of virus doses and significant anti-tumor activity occurs at doses of ganciclovir which have been clinically achievable. Finally, this treatment approach appears safe, with limited dissemination of virus utilizing a sensitive RT-PCR detection system. These studies further characterize the application of adenoviral transfer of the HSVtk gene to cure experimental mesothelioma and advise that numerous studies using this approach might be feasible.
Another interesting study is, “The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: A comparative study Human pathology” by ORDONEZ Nelson G. – 2004, vol. 35, no6, pp. 697-710 [14 page(s) (article)] (92 ref.) We have found an excerpt: “Abstract – Both mesotheliomas and renal cell carcinomas can instruct an array of morphological patterns. Therefore, renal cell carcinomas that metastasize towards pleura and lung may perhaps be mistaken for mesotheliomas. The essence this current study would have been to compare the power of different immunohistochemical markers you can buy to your proper diagnosis of mesothelioma and renal cell carcinoma. At all times . 48 mesotheliomas (40 epithelioid, 8 sarcomatoid), and 48 renal cell carcinomas (24 conventional, 12 chromophobe, 8 papillary, 4 sarcomatoid) were investigated to the expression within the following markers: calretinin, mesothelin, cytokeratin 5/6, WT1, thrombomodulin (TM), N-cadherin, CD15 (leu-M1), MOC-31, Ber-EP4, BG-8 (Lewisy), CD10, renal cell carcinoma marker (RCC Ma), carcinoembryonic antigen (CEA), and B72.3. All (100%) in the epithelioid mesotheliomas reacted for calretinin, mesothelin, and cytokeratin 5/6; 93% for WT1; 78% for TM; 75% for N-cadherin, 48% for CD10, 15% for Ber-EP4,8% for MOC-31, 8% for RCC Ma, 5% for BG-8, and none for CEA, B72.3, or CD15. Within the sarcomatoid mesotheliomas, 88% expressed calretinin, 75% N-cadherin, 38% CD10, and 13% each expressed cytokeratin 5/6, WT1, and TM. Many of the remaining markers were negative. On the list of RCCs, 81% expressed CD10, 75% N-cadherin, 63% CD15, 50% RCC Ma, 50% MOC-31, 42% Ber-EP4, 8% BG-8, and 2% TM. The remainder of the markers were negative. The end result indicate that calretinin, mesothelin, and cytokeratin 5/6 are the most effective positive mesothelioma markers for differentiating epithelioid mesotheliomas from renal cell carcinomas. The top discriminators one of the antibodies considered negative markers for mesothelioma are CD15, MOC-31, and RCC Ma. A definitive differential diagnosis can be reached through any 2 within the 3 recommended positive markers, which will be selected based upon availability is without a doubt the ones yield the best staining leads to a given laboratory. One of many recommended negative markers can be included with the panel if deemed necessary. If confirmation of renal origin ought to be required, RCC Ma can be useful. Calretinin stands out as the only marker that appears to acquire any utility in distinguishing between sarcomatoid mesotheliomas and sarcomatoid renal cell carcinomas.” We all owe a debt of gratitude to fine researchers. Should you found such excerpts interesting, please browse the studies of their entirety. Monty Wrobleski is the author as soon as i’ve. For additional information please click the following links Mesothelioma Attorney Mesothelioma Lawyer Mesothelioma Lawyer
No comments:
Post a Comment